 | Up a level |
Agostinetto, Elisa 
ORCID: 0000-0003-0295-7511, Ameye, Lieveke, Martel, Samuel, Aftimos, Philippe, Ponde, Noam, Maurer, Christian ORCID: 0000-0003-4388-5163, El-Abed, Sarra, Wang, Yingbo, Vicente, Malou, Chumsri, Saranya, Bliss, Judith ORCID: 0000-0001-7957-7424, Kroep, Judith, Colleoni, Marco, Petrelli, Fausto, Del Mastro, Lucia, Moreno-Aspitia, Alvaro, Piccart, Martine, Paesmans, Marianne, de Azambuja, Evandro and Lambertini, Matteo ORCID: 0000-0003-1797-5296
(2022).
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
npj Breast Cancer, 8 (1).
BERLIN:
NATURE PORTFOLIO.
ISSN 2374-4677
Ferreira, Arlindo R., Ferreira, Sofia, Lambertini, Matteo ORCID: 0000-0003-1797-5296, Maurer, Christian, Martel, Samuel, Costa, Luis, Ponde, Noam and de Azambuja, Evandro ORCID: 0000-0001-9501-4509
(2021).
Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
Eur. J. Cancer, 144.
S. 351 - 360.
OXFORD:
ELSEVIER SCI LTD.
ISSN 1879-0852
Ferreira, Arlindo R., Ponde, Noam, Lambertini, Matteo, Maurer, Christian, Martel, Samuel, Costa, Luis and De Azambuja, Evandro (2020). Association between pertuzumab (P) induced diarrhea and skin rash and survival outcomes in patients (pts) with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trial. Cancer Res., 80 (4). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Martel, Samuel, Maurer, Christian, Lambertini, Matteo ORCID: 0000-0003-1797-5296, Ponde, Noam and De Azambuja, Evandro
(2017).
Breast cancer treatment-induced cardiotoxicity.
Expert Opin. Drug Saf., 16 (9).
S. 1021 - 1039.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1744-764X
Maurer, Christian, Ferreira, Arlindo R., Martel, Samuel, Lambertini, Matteo ORCID: 0000-0003-1797-5296, Ponde, Noam, Aftimos, Philippe, de Azambuja, Evandro ORCID: 0000-0001-9501-4509 and Piccart, Martine
(2018).
Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.
Breast, 39.
S. 14 - 19.
EDINBURGH:
CHURCHILL LIVINGSTONE.
ISSN 1532-3080